Target Name: VWCE
NCBI ID: G220001
Review Report on VWCE Target / Biomarker Content of Review Report on VWCE Target / Biomarker
VWCE
Other Name(s): von Willebrand factor C and EGF domains | HBV X protein up-regulated gene 11 protein | Von Willebrand factor C and EGF domain-containing protein | VWCE_HUMAN | URG11 | HBxAg up-regulated gene 11 protein | von Willebrand factor C and EGF domain-containing protein | Von Willebrand factor C and EGF domains | VWC1

Discovery of VWF as A Drug Target

Von Willebrand factor (VWF) is a transmembrane protein that is expressed in various tissues and plays a crucial role in blood clotting. The VWF gene encodes a protein that consists of two constant (C) and two variable (EGF) domains. The C domain is responsible for the protein's transmembrane characteristics, while the EGF domain is involved in the interaction with the EGFR receptor. VWF is a key regulator of blood clotting and has been implicated in the development and progression of various cardiovascular diseases.

The discovery of VWF as a drug target

VWF has been a drug target for several years, with several studies targeting the VWF C-domain. The first study identified a potential drug target in the VWF C-domain, which is located at amino acid position 129. This study identified a unique residue, Asp132, which is important for the stability of the VWF C-domain.

Subsequent studies have further confirmed the importance of Asp132 in VWF function. In one study, researchers found that Asp132 was important for the stability of the VWF C-domain and that the substitution of Asp132 with Asp133 had a significant impact on the stability of the domain.

Another study found that Asp132 plays a role in the regulation of the growth and differentiation of hematopoietic stem cells (HSCs). This suggests that Asp132 may be a potential drug target for HSCs.

The EGF domain of VWF is also under investigation as a drug target. The EGF domain is responsible for the interaction with the EGFR receptor, which is a key regulator of cell growth and survival. Several studies have identified potential drug targets in the EGF domain, including Ser184 and Asp211.

The potential implications of targeting VWF

Targeting VWF as a drug or biomarker has significant potential in the field of cardiovascular diseases. VWF is involved in the regulation of blood clotting, which is a critical function for maintaining cardiovascular health. Therefore, targeting VWF as a drug or biomarker may have a significant impact on the treatment of cardiovascular diseases.

One potential drug target for VWF is the inhibition of the aggregation of platelets, which is a key event in the formation of blood clots. This can be achieved by targeting the VWF C-domain, which is responsible for the regulation of the structure and function of the protein.

Another potential drug target for VWF is the inhibition of the growth and differentiation of cancer cells, which is a critical event in the development of cancer. This can be achieved by targeting the EGF domain, which is responsible for the interaction with the EGFR receptor.

Conclusion

Von Willebrand factor (VWF) is a transmembrane protein that is involved in the regulation of various physiological processes in the body. The discovery of VWF as a drug target has significant potential in the field of cardiovascular diseases. Targeting VWF as a drug or biomarker may have a significant impact on the treatment of cardiovascular diseases. Further research is needed to fully understand the potential of VWF as a drug target and to develop effective treatments.

Protein Name: Von Willebrand Factor C And EGF Domains

Functions: May be a regulatory element in the beta-catenin signaling pathway and a target for chemoprevention of hapatocellular carcinoma

The "VWCE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VWCE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1